the hepatitis b pipeline is a complex process that is characterized by the development of a curative combination regimen that includes several different mechanisms of action. in this article, we present the meeting meeting and discuss the current status of our lead compounds, b-506 and b-729, and the potential for our drug candidates to improve upon standard of care and contribute to a curative combination regimen for human hepatitis b.